A Phase II, Double-Blind, Randomised, Controlled, Multi-Centre Study to Evaluate the Immunogenicity, Safety and Tolerability of Three Formulations of CSL412 in Adults (18 to 45 Years) and Older Adults (greater than or equal to 60 Years).
Phase of Trial: Phase II
Latest Information Update: 21 Jul 2016
At a glance
- Drugs CSL 412 (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors CSL
- 24 Mar 2012 Planned patient number is 720 according to European Clinical Trials Database.
- 23 Jan 2008 The expected completion date for this trial is now 1 Aug 2007.
- 29 Jul 2007 New trial record.